Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sustained Release Oral Formulation for Treatment of Parkinson's Disease
Sponsor: University of Minnesota
Summary
Achieving sustained blood levels of carbidopa/levodopa has been a challenge in the treatment of PD and although levodopa remains the most commonly used drug, motor fluctuations remain a major disability especially in advanced Parkinson's disease. The aim of this study is to determine the efficacy of a novel oral carbidopa-levodopa formulation in achieving a sustained blood level of levodopa and carbidopa in normal volunteers.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
6
Start Date
2025-06-12
Completion Date
2026-06-16
Last Updated
2025-07-10
Healthy Volunteers
Yes
Conditions
Interventions
levodopa/carbidopa oral formulation A
Outer sachet 100mg CD/100mg LD and inner sachet 0mg CD /300mg LD
levodopa/carbidopa oral formulation B
Outer sachet 100mg CD/0mg LD and inner sachet 0mg CD /400mg LD
Locations (1)
University of Minnesota
Minneapolis, Minnesota, United States